Gain detailed insights into the trading activity of Congress members for argenx on our government trades page. Stay updated on how elected officials are investing in ARGX.

argenx - Government Trades

argenx

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

wall-street-ai17

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARGX

GRFS

SNOW

USAP

UXIN

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Johnson Johnson logo in front of one of their office buildings, Fremont, East San Francisco bay area, California. Image By Sundry Photography Via Shutterstock

Biotech

Large Cap

Health Care

General

UCBJF

UCBJY

Johnson &amp; Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows positive Phase 3 study results and could position nipocalimab as a key competitor against existing gMG treatments like UCB&#39;s Rystiggo and Argenx&#39;s Vyvgart.

Johnson &amp; Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

Upgrades

Analyst Ratings

CRWD

LION

LUMN

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Image 6

Price Target

CGNX

CHTR

DAIO

LGVN

MPWR

SCHW

TXRH

Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Earnings

Penny Stocks

Small Cap

ARQT

HRTX

Shares of Argenx (NASDAQ: ARGX) rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart Hytrulo (efgartigimod) for a second indication — chronic inflammatory demyelinating polyneuropathy (CIDP).

FDA Expands Argenx&#39;s Vyvgart Label to Treat Rare Disorder

Medical,Examination,And,Healthcare,Business,Graph,,,Health,Insurance,,Health

Analyst Color

Equities

Reiteration

The FDA has approved Argenx&#39;s Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.

Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

Micron Stock

PLNT

SIRI

SRPT

Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday

Stocks Photo by Jirapong Manustrong on Shutterstock

ALNY

CLOV

IONS

NTLA

PHAR

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

BHVN

IMVT

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study

Wall Street US stocks

Intraday Update

ABNB

AIXI

ALGM

ALTG

ASLE

BIGC

BLBD

BNED

BYND

CAMT

CCSI

CDLX

COMP

CPOP

CRNC

CTMX

DUOL

EMBC

EMKR

EPAM

EQIX

EXAS

FWRD

GLOB

GWAV

IHRT

IRWD

KVYO

LFMD

MGNI

PENN

PLTK

PYCR

RAPT

RBLX

SBGI

SEDG

SEZL

SITM

SKYT

STVN

SYRA

TIVC

TIXT

VITL

WRBY

YETI

ZIMV

ZLAB

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

argenx SE

Keefe, Bruyette &amp; Woods analyst Kelly Motta upgrades CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) from Market Perform to Outperform and raises the price target from $20 to $22.

CVBF

Keefe, Bruyette & Woods Upgrades CVB Financial to Outperform, Raises Price Target to $22

Evercore ISI Group analyst John Pancari upgrades M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from In-Line to Outperform and raises the price target from $187 to $210.

Evercore ISI Group Upgrades M&T Bank to Outperform, Raises Price Target to $210

Contracts

Jacobs Will Expand Its Portfolio Of Digital And Data-driven Solutions With A New Five-year Contract With Lincoln-sewer Management District 1 Wastewater Authority – A Joint Powers Authority Between The City Of Lincoln And Placer County In California

Evercore ISI Group analyst David Motemaden assumes Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) with a In-Line rating and announces Price Target of $279.

Initiation

VRSK

Evercore ISI Group Assumes Verisk Analytics at In-Line, Announces Price Target of $279

Economist and macro trader Alex Krüger voiced caution about the sudden market optimism, coined as "Uptober", highlighting the looming uncertainty of the U.S. election year and its potential impact <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41126018/bitcoin-plunges-below-62k-as-iran-launches-missile-attack-on-israel">on market volatility</a>.
What Happened: Krüger highlighted the unexpected bullishness following the last FOMC meeting but emphasized that it was two weeks ago, and the situation has since evolved.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>7-Day Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$61,085</td>
<td>-3.9%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2.452</td>
<td>&nbsp;-6.5%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$145.98</td>
<td>&nbsp;-2.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1063</td>
<td>&nbsp;-2.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001662</td>
<td>&nbsp;+10.4%</td>
</tr>
</tbody>
</table>
</figure>
Despite ongoing conflicts in the Middle East, Krüger pointed out that the major uncertainty lies in the upcoming <a href="https://www.benzinga.com/news/24/10/41136119/vance-vs-walz-flash-poll-picks-this-candidate-as-tuesdays-debate-winner-but-he-falls-short-in-favora">U.S. elections</a>. He stated, "Who wins does make a big difference. Particularly so if the Democrats win a clean sweep."
In response to the reactions of crypto twitter, Krüger also stated that if "Trump does well in the last month crypto should outperform." He believes nothing material will change and Bitcoin could be between $62,000 to $65,000 going into election night.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41124852/bitcoin-halving-cycle-signals-potential-2024-rally-canaccord-analysts-predict">What Does Technical Analysis Say About Bitcoin?</a>
Why It Matters: Krüger <a href="https://x.com/krugermacro/status/1841398125375750387">warned</a> that speculators do not favor uncertainty, and historically, October has been the most volatile month in election years, with equities showing slightly negative returns. He dismissed the notion that a positive September guarantees a positive October as a &#8220;spurious correlation.&#8221;
He did acknowledge that strong payrolls this coming Friday could boost equities, given the current &#8220;good news is good news&#8221; regime. But he advised that the prudent time to press and hold is after the elections, possibly starting on election night itself.
The JOLTs Job Openings for August on Tuesday came in at 8.04 million compared to the 7.64 million expected and 7.71 million reported in prior month. The non-farm payrolls data on Friday are <a href="https://www.investing.com/economic-calendar/">expected</a> to come in at 144,000 for September compared to the 142,000 reported for August.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41124852/bitcoin-halving-cycle-signals-potential-2024-rally-canaccord-analysts-predict">Bitcoin Halving Cycle Signals Potential 2024 Rally, Canaccord Analysts Predict</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

Why Bitcoin's 'Uptober' Won't Be A Smooth Ride: It's The Election, Silly

Natural Grocers&#39; good4uSM&nbsp;Crew will begin store-wide closing sales on October 4, with discounts of&nbsp;10%&nbsp;off everything at the&nbsp;1433 Washington St. location. All sales will be final.
Natural Grocers states the decision to close the store was made after careful consideration of the operating challenges, including retail theft and safety issues impacting the store&#39;s performance.

NGVC

Natural Grocers Plans To Close Its Downtown Denver Store Located At The Corner Of Colfax And Washington, On October 31; Cites Retail Theft And Safety Issues

Evercore ISI Group analyst David Motemeden initiates coverage on S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform rating and announces Price Target of $599.

SPGI

Evercore ISI Group Initiates Coverage On S&P Global with Outperform Rating, Announces Price Target of $599

Evercore ISI Group analyst David Motemeden initiates coverage on Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Outperform rating and announces Price Target of $521.

Evercore ISI Group Initiates Coverage On Moodys with Outperform Rating, Announces Price Target of $521

Evercore ISI Group analyst David Motemeden initiates coverage on MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Outperform rating and announces Price Target of $690.

MSCI

Evercore ISI Group Initiates Coverage On MSCI with Outperform Rating, Announces Price Target of $690

WIIM

LPLA

LPL Financial Holdings shares are trading lower after the company announced it terminated CEO Dan Arnold for violating its commitment to a respectful workplace.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Announced That Multiple Oral And Poster Presentations Were Presented At The International Congress Of Parkinson's Disease And Movement Disorders

Evercore ISI Group analyst David Motemeden initiates coverage on FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a In-Line rating and announces Price Target of $470.

Evercore ISI Group Initiates Coverage On FactSet Research Systems with In-Line Rating, Announces Price Target of $470

Conagra Brands Is Reaffirming Its Fiscal 2025 Guidance: Projects Organic Net Sales Of (1.5)% To Flat Compared To FY24, Sees Adjusted EPS Between $2.60-$2.65 Vs. $2.61 Estimate

XAIR

Beyond Air Announced Entering A Strategic Partnership With Healthcare Links To Focus On Expanding Access To Beyond Air's LungFit PH System

Emergent Biosolutions Announced The Closing Of Credit Agreement Worth $100M Entered On September 30, 2024 Providing For An Asset-based Revolving Loan Facility

ConAgra Brands shares are trading lower after the company reported worse-than-expected Q1 financial results.

Northland Capital Markets analyst Nehal Chokshi upgrades Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Market Perform to Outperform and raises the price target from $270 to $400.

Northland Capital Markets Upgrades Salesforce to Outperform, Raises Price Target to $400

NRGV

Energy Vault Announced Ownership of Energy Storage Projects and Launches Project Financing For Select U.S. Projects

This facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials.
Opening in late 2027, the facility will increase Lilly&#39;s total capital commitment in&nbsp;the United States&nbsp;to more than&nbsp;$23 billion&nbsp;since 2020

Eli Lilly Reveals $4.5B Investment To Create The Lilly Medicine Foundry For Advanced Manufacturing And Drug Development

CME Reported Its Q3 And September 2024 Market Statistics, With Average Daily Volume Reaching New, All-time Records Of 28.3M Contracts In Q3 And 28.4M Contracts In The Month Of September, And Growth Across All Asset Classes In Both Periods

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

Analyst Derek Archila of Wells Fargo reiterated a Buy rating on Argenx Se (ARGX – Research Report), retaining the price target of $547.00. Derek Ar...

Buy Rating Affirmed for Argenx Se Amid Vyvgart's Favorable Efficacy and Safety Profile Over Uplizna

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target o...

Piper Sandler Reaffirms Their Buy Rating on Argenx Se (ARGX)

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ARGX stock, giving a Buy rating today. Tazeen Ahmad's rating...

Buy Rating Affirmed for Argenx Se on Vyvgart's Strong Market Potential in gMG Treatment

Argenx Se (ARGX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Akash Tewari from Jeff...

Buy Rating Justified: Argenx Se's Vyvgart Outshines Uplizna in gMG Treatment Efficacy and Safety

Amgen stock slides 5% as analysts weigh in on drug study results

Amgen stock slides 5% as analysts weigh in on drug study results (update)

Truist Financial analyst Joon Lee maintained a Buy rating on Argenx Se (ARGX – Research Report) today. The company's shares closed yesterday at $54...

Truist Financial Remains a Buy on Argenx Se (ARGX)

Kepler Capital analyst Christophe dombu maintained a Buy rating on arGEN X (0QW0 – Research Report) on September 25 and set a price target of €545....

arGEN X (0QW0) Receives a Buy from Kepler Capital

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Government Trades

argenx SE

top performing ARGX trades